The Claim
In human liver cell lines exposed to free fatty acids, treatment with recombinant IGFBP1 reduces lipid accumulation and suppresses activation of the NF-κB and ERK inflammatory signaling pathways.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In human liver cells exposed to free fatty acids, recombinant IGFBP1 decreases fat buildup and reduces activity in the NF-κB and ERK inflammatory signaling pathways.
See the scientific wording
In human liver cell lines exposed to free fatty acids, treatment with recombinant IGFBP1 reduces lipid accumulation and suppresses activation of the NF-κB and ERK inflammatory signaling pathways.
When IGFBP1 attaches to integrin β1 on liver cells, it turns off genes that make fat and turns on genes that burn fat, while also blocking two key inflammation signals, NF-κB and ERK, which stops the cells from producing inflammatory chemicals.
What the research says
1 studyWhen scientists added IGFBP1 to human liver cells overloaded with fats, the cells stored less fat and showed less inflammation — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.